Antimicrobial resistance of <i>Pseudomonas aeruginosa</i>: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Simple item page
dc.contributor.authorElfadadny, Ahmed
dc.contributor.authorRagab, Rokaia F.
dc.contributor.authorAlHarbi, Maha
dc.contributor.authorBadshah, Farhad
dc.contributor.authorIbanez Arancibia, Eliana
dc.contributor.authorFarag, Ahmed
dc.contributor.authorHendawy, Amin Omar
dc.contributor.authorDe los Rios Escalante, Patricio R.
dc.contributor.authorAboubakr, Mohamed
dc.contributor.authorZakai, Shadi A.
dc.contributor.authorNageeb, Wedad M.
dc.date2024
dc.date.accessioned2024-05-27T18:27:20Z
dc.date.available2024-05-27T18:27:20Z
dc.description.abstractPseudomonas aeruginosa, a Gram-negative bacterium, is recognized for its adaptability and opportunistic nature. It poses a substantial challenge in clinical settings due to its complicated antibiotic resistance mechanisms, biofilm formation, and capacity for persistent infections in both animal and human hosts. Recent studies revealed a potential zoonotic transmission of P. aeruginosa between animals, the environment, and human populations which highlights awareness of this microbe. Implementation of the One Health approach, which underscores the connection between human, animal, and environmental health, we aim to offer a comprehensive perspective on the current landscape of P. aeruginosa management. This review presents innovative strategies designed to counteract P. aeruginosa infections. Traditional antibiotics, while effective in many cases, are increasingly compromised by the development of multidrug-resistant strains. Non-antibiotic avenues, such as quorum sensing inhibition, phage therapy, and nanoparticle-based treatments, are emerging as promising alternatives. However, their clinical application encounters obstacles like cost, side effects, and safety concerns. Effectively addressing P. aeruginosa infections necessitates persistent research efforts, advancements in clinical development, and a comprehension of host-pathogen interactions to deal with this resilient pathogen.
dc.identifier.citationFRONTIERS IN MICROBIOLOGY,Vol.15,2024
dc.identifier.doi10.3389/fmicb.2024.1374466
dc.identifier.urihttps://repositoriodigital.uct.cl/handle/10925/5747
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.sourceFRONTIERS IN MICROBIOLOGY
dc.subject.englishPseudomonas aeruginosa
dc.subject.englishresistance
dc.subject.englishpathogenicity
dc.subject.englishvirulence
dc.subject.englishtherapy
dc.titleAntimicrobial resistance of <i>Pseudomonas aeruginosa</i>: navigating clinical impacts, current resistance trends, and innovations in breaking therapies
dc.typeReview
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science